Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.

Savelieva I, Camm J.

Europace. 2008 Jun;10(6):647-65. doi: 10.1093/europace/eun130. Review.

PMID:
18515286
2.

Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy.

Bhavnani SP, Coleman CI, White CM, Clyne CA, Yarlagadda R, Guertin D, Kluger J.

Europace. 2008 Jul;10(7):854-9. doi: 10.1093/europace/eun128. Epub 2008 May 20.

PMID:
18495672
3.

N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study.

Ozaydin M, Peker O, Erdogan D, Kapan S, Turker Y, Varol E, Ozguner F, Dogan A, Ibrisim E.

Eur Heart J. 2008 Mar;29(5):625-31. doi: 10.1093/eurheartj/ehn011. Epub 2008 Feb 8.

PMID:
18263874
4.

Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.

Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH; EURIDIS and ADONIS Investigators.

N Engl J Med. 2007 Sep 6;357(10):987-99.

5.

Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.

Dale KM, White CM.

Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. Review.

PMID:
17389667
6.

Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.

Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, Nattel S.

Circulation. 2007 Jan 23;115(3):310-8. Epub 2007 Jan 15.

7.

Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009.

Crijns HJ, Van Gelder IC, Walfridsson H, Kulakowski P, Rónaszéki A, Dedek V, Malm A, Almgren O.

Heart Rhythm. 2006 Nov;3(11):1321-31. Epub 2006 Jul 8.

PMID:
17074639
8.

Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure.

Lee KW, Everett TH 4th, Rahmutula D, Guerra JM, Wilson E, Ding C, Olgin JE.

Circulation. 2006 Oct 17;114(16):1703-12. Epub 2006 Oct 9.

9.
10.

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.

Anand K, Mooss AN, Hee TT, Mohiuddin SM.

Am Heart J. 2006 Aug;152(2):217-22.

PMID:
16875900
11.

Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation.

Guerra JM, Everett TH 4th, Lee KW, Wilson E, Olgin JE.

Circulation. 2006 Jul 11;114(2):110-8. Epub 2006 Jul 3.

12.

Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation.

Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS, Stewart AF, Tesson F, Klein GJ, Yee R, Skanes AC, Guiraudon GM, Ebihara L, Bai D.

N Engl J Med. 2006 Jun 22;354(25):2677-88.

13.

Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study.

Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Witteman JC.

Am Heart J. 2006 Apr;151(4):857-62.

PMID:
16569549
14.

Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.

Boos CJ, Lip GY.

J Am Coll Cardiol. 2006 Feb 21;47(4):889-90; author reply 890-1. Epub 2006 Jan 26. No abstract available.

15.
16.

Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence.

Ehrlich JR, Hohnloser SH, Nattel S.

Eur Heart J. 2006 Mar;27(5):512-8. Epub 2005 Nov 25. Review.

PMID:
16311236
17.

The mechanism of atrial antiarrhythmic action of RSD1235.

Fedida D, Orth PM, Chen JY, Lin S, Plouvier B, Jung G, Ezrin AM, Beatch GN.

J Cardiovasc Electrophysiol. 2005 Nov;16(11):1227-38.

PMID:
16302909
18.
19.

New antiarrhythmic drugs for prevention of atrial fibrillation.

Goldstein RN, Stambler BS.

Prog Cardiovasc Dis. 2005 Nov-Dec;48(3):193-208. Review.

PMID:
16271945
20.

N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial.

Calò L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, Pandozi C, Staibano M, Santini M.

J Am Coll Cardiol. 2005 May 17;45(10):1723-8.

Supplemental Content

Support Center